Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01337245 · ClinicalTrials.gov registry record · Phase 3

Emergency Treatment of Coral Snake Envenomation With Antivenom

A Phase 3 study of Coral Snake Bite and Toxic Effect of Coral Snake Venom, sponsored by University of Arizona.

Completed
Registry status
Phase 3
Development phase
26
Enrollment target
5
Study locations

NCT01337245 is a Phase 3 study of Coral Snake Bite and Toxic Effect of Coral Snake Venom that has completed, run by University of Arizona. The registered enrollment target is 26 participants. The trial reports 5 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01337245, a Phase 3 study of Coral Snake Bite and Toxic Effect of Coral Snake Venom, has completed, sponsored by University of Arizona.

COMPLETED
Registry status
Phase 3
Development phase
26 participants
Enrollment target
5
Study locations

Study Summary

The purpose of this study is to see whether a new F(ab')2 antivenom will prevent injury and death from the bite of a coral snake. Funding Source - FDA OOPD.

Interventions

  • DRUG Snake (Micrurus) North American immune F(ab')2 Equine

Study Locations (5)

Florida

  • Florida Hospital Deland - DeLand
  • Lee Memorial Hospital - Fort Myers
  • St. Lucie Medical Center - Port Saint Lucie
  • Tampa General Hospital - Tampa

Arizona

  • Banner University Medical Center - Tucson

Trial Details

FieldValue
Enrollment Target 26 participants
Start Date 2012-05
Est. Completion 2016-11-11
Phase Phase 3

Sponsor

University of Arizona

349 total trials

What the Registry Record Tells You About NCT01337245

The ClinicalTrials.gov registry entry for NCT01337245 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Coral Snake Bite appearing as the primary indexed condition, and to 1 intervention - of which Snake (Micrurus) North American immune F(ab')2 Equine is the first listed.

NCT01337245 reports 5 study locations spanning 2 distinct geographic areas - top geographies include Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT01337245 about?

NCT01337245 is a clinical study titled "Emergency Treatment of Coral Snake Envenomation With Antivenom". The purpose of this study is to see whether a new F(ab')2 antivenom will prevent injury and death from the bite of a coral snake. Funding Source - FDA OOPD.

What is the current status of trial NCT01337245?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 26 participants. The study started on 2012-05. Estimated completion is 2016-11-11.

What conditions does trial NCT01337245 study?

This clinical trial studies the following conditions: Coral Snake Bite, Toxic Effect of Coral Snake Venom.

What interventions are being tested in trial NCT01337245?

The interventions under investigation include: Snake (Micrurus) North American immune F(ab')2 Equine (DRUG).

Who is sponsoring clinical trial NCT01337245?

This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01337245 being conducted?

This trial has 5 study locations across Arizona, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.